Cambridge Heart Sees Strong Growth, Despite Blue Cross’ Negativity
This article was originally published in The Gray Sheet
Executive Summary
The Blue Cross Blue Shield Association has reaffirmed its negative assessment of microvolt T-wave alternans testing to risk-stratify candidates for ICD therapy, despite accelerating market adoption that is driving sales growth for MTWA test maker Cambridge Heart